Saturday, July 11, 2026

pharma · Chronic Obstructive Pulmonary Disease · Tuberculosis

Anhui Huaheng Biotechnology

Anhui Hemay Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease, Tuberculosis. NovaPharmaNews links 2 clinical program(s), 0 drug pro

Hefei, CN HQ
2005 Founded
32 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Hefei, CN
Founded
2005
Employees
32
Programs
2
Drugs
6
Patents
0

Quick answer

Anhui Hemay Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease, Tuberculosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (2).

Company snapshot

Key words: AMINO ACID, ALANINE, ARBUTIN, MANUFACTURER. Anhui Huaheng Biological Engineering Co., Ltd. was established in April 2005, is a professional engaged in amino acids and other organic acid product development, production and sales of national Torch key high-tech enterprises. The company has successfully undertaken the "863" project of the Ministry of Science and Technology of the Twelfth F

  • 2 active pipeline program(s) linked via ClinicalTrials.gov.
  • 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Anhui Huaheng Biotechnology. Not investment advice.

Lead pipeline drugs

Active clinical programs

Momentum signals

Momentum

Proprietary activity score for Anhui Huaheng Biotechnology.

1 active signal

13 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 2 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d
Competitive landscape
Recent activity

Recent activity

Latest pipeline, patent, and corporate events for Anhui Huaheng Biotechnology.

  1. Clinical update

    Purified Protein Derivative of BCG(BCG-PPD) — Phase 1

  2. Clinical update

    Hemay005 tablet — Phase 1

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Anhui Huaheng Biotechnology?

    Anhui Hemay Pharmaceutical is a pharma organization headquartered in CN. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease, Tuberculosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public F

  • Is Anhui Huaheng Biotechnology publicly traded?

    Anhui Huaheng Biotechnology appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Anhui Huaheng Biotechnology develop or market?

    We link 6 drug profile(s) where Anhui Huaheng Biotechnology is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/anhui-hemay-pharmaceutical-co-ltd#company-drugs.

  • What are the latest developments for Anhui Huaheng Biotechnology?

    In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Anhui Huaheng Biotechnology focus on?

    Anhui Huaheng Biotechnology focuses on Chronic Obstructive Pulmonary Disease, Tuberculosis based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
5